Improvement in attention/memory domains in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel is associated with better quality of life
Objective: To evaluate the relationship between non-motor symptom (NMS) severity, quality of life (QoL), and activities of daily living (ADL) in advanced Parkinson’s disease (PD)…Effects of the administration of levodopa on postural control under visual tasks
Objective: We tested if the administration of levodopa leads the patients with Parkinson’s disease to sway significantly more than the controls, especially under challenging visual…Medication optimization in Parkinson’s disease patients with ON-state freezing using objective gait assessments
Objective: To determine whether objective gait assessments could guide therapeutic decision making in Parkinson’s disease (PD) patients reporting freezing of gait (FOG) in the levodopa-ON…Safety of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients receiving ≥ 2000 mg daily dose of levodopa
Objective: To examine the safety of levodopa-carbidopa intestinal gel treatment (LCIG, carbidopa-levodopa enteral suspension in the US) in advanced Parkinson’s disease (PD) patients that received…Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease
Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…Factors associated with occurrence of motor complications among Parkinson’s disease patients with levodopa treatment in Estonia
Objective: To identify the factors associated with the occurrence of motor complications among patients with Parkinson’s disease (PD) who receive levodopa treatment. Background: Levodopa is the…A long-term study on effectiveness of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients
Objective: To present the design of and baseline patient characteristics from an ongoing global study assessing the long-term effectiveness of levodopa-carbidopa intestinal gel (LCIG, carbidopa-levodopa…An Unusual Cause of Rhabdomyolysis in Parkinson’s disease
Objective: To describe an unusual cause of rhabdomyolysis in patient with advanced Parkinson’s disease (PD) treated with levodopa. Background: Rhabdomyolysis is a serious and life-threatening…Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.
Objective: To define variation in L-dopa response in recent onset PD. Background: L-Dopa responsiveness is a defining feature of Parkinson’s disease (PD), but the degree…Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study
Objective: Evaluate the efficacy and safety of IPX203 vs. immediate-release (IR) carbidopa-levodopa (CD-LD) and vs. extended-release (ER) CD-LD (IPX066, RYTARY®) in patients with advanced Parkinson’s…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 62
- Next Page »